NCT01185821 - Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis | Biotech Hunter

Enrollment

185

Participants

Timeline

Start Date

August 30, 2010

Primary Completion Date

October 10, 2016

Study Completion Date

October 10, 2016

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

BAF312

BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.

Trial Locations (46)

1076

Novartis Investigative Site, Budapest

1145

Novartis Investigative Site, Budapest

4031

Novartis Investigative Site, Basel

4032

Novartis Investigative Site, Debrecen

5021

Novartis Investigative Site, Bergen

6900

Novartis Investigative Site, Lugano

8091

Novartis Investigative Site, Zurich

25018

Novartis Investigative Site, Montichiari

29607

Novartis Investigative Site, Greenville

32308

Novartis Investigative Site, Tallahassee

33060

Novartis Investigative Site, Pompano Beach

33136

Novartis Investigative Site, Miami

34093

Novartis Investigative Site, Istanbul

34096

Novartis Investigative Site, Haseki / Istanbul

35340

Novartis Investigative Site, Izmir

41009

Novartis Investigative Site, Seville

41380

Novartis Investigative Site, Kocaeli

44320

Novartis Investigative Site, Akron

46026

Novartis Investigative Site, Valencia

48149

Novartis Investigative Site, Münster

49477

Novartis Investigative Site, Ibbenbueren

49525

Novartis Investigative Site, Grand Rapids

60637

Novartis Investigative Site, Chicago

66100

Novartis Investigative Site, Chieti

81675

Novartis Investigative Site, München

98122

Novartis Investigative Site, Seattle

125367

Novartis Investigative Site, Moscow

127018

Novartis Investigative Site, Moscow

194044

Novartis Investigative Site, Saint Petersburg

197022

Novartis Investigative Site, Saint Petersburg

420103

Novartis Investigative Site, Kazan'

K1H 8L6

Novartis Investigative Site, Ottawa

J9J 0A5

Novartis Investigative Site, Gatineau

J4V 2J2

Novartis Investigative Site, Greenfield Park

00930

Novartis Investigative Site, Helsinki

FIN-33520

Novartis Investigative Site, Tampere

01307

Novartis Investigative Site, Dresden

H-8200

Novartis Investigative Site, Veszprém

00133

Novartis Investigative Site, Roma

00152

Novartis Investigative Site, Roma

0424

Novartis Investigative Site, Oslo

90-324

Novartis Investigative Site, Lodz

20-954

Novartis Investigative Site, Lublin

02-957

Novartis Investigative Site, Warsaw

08035

Novartis Investigative Site, Barcelona

06100

Novartis Investigative Site, Ankara